Sage Therapeutics $SAGE gave additional positive data from Phase 2 clinical trial of SAGE-547 intended for patients with severe postpartum depression at the Marce Society for Perinatal Mental Health Biennial Scientific Meeting. The candidate was found to be well-tolerated with no severe adverse events reported during treatment and follow-up periods. The topline results from both trials are expected next year. Secondary endpoints demonstrated significant difference in improvement from baseline for SAGE-547 compared to placebo over 3 weeks.